Stock 688363 BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bloomage BioTechnology Corporation Limited

Equities

688363

CNE100003NL9

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-22 pm EDT 		5-day change 1st Jan Change
61.1 CNY -5.34% Intraday chart for Bloomage BioTechnology Corporation Limited -1.59% -8.71%
Apr. 29 Bloomage BioTechnology Corporation Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 02 Tranche Update on Bloomage BioTechnology Corporation Limited's Equity Buyback Plan announced on August 17, 2023. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 40,032 70,286 74,544 65,081 32,239 29,245 - -
Enterprise Value (EV) 1 40,032 70,286 72,968 63,812 31,225 27,974 27,760 27,383
P/E ratio 68.4 x 108 x 95.9 x 67.3 x 54.4 x 34.8 x 26.2 x 23.4 x
Yield 0.44% 0.28% 0.32% 0.45% 0.57% 0.85% 1.1% 1.19%
Capitalization / Revenue 21.2 x 26.7 x 15.1 x 10.2 x 5.31 x 4.28 x 3.55 x 3.21 x
EV / Revenue 21.2 x 26.7 x 14.7 x 10 x 5.14 x 4.09 x 3.37 x 3 x
EV / EBITDA 53.1 x 84.5 x 70.6 x 48.6 x 33.2 x 22.6 x 18.2 x 15.4 x
EV / FCF - - 148 x -1,064 x -94.4 x -40.7 x 24.1 x 24.8 x
FCF Yield - - 0.67% -0.09% -1.06% -2.46% 4.15% 4.04%
Price to Book 8.8 x 14 x 13.1 x 9.81 x 4.64 x 3.89 x 3.46 x 3.16 x
Nbr of stocks (in thousands) 480,000 480,000 480,000 481,085 481,678 478,638 - -
Reference price 2 83.40 146.4 155.3 135.3 66.93 61.10 61.10 61.10
Announcement Date 2/28/20 2/25/21 2/25/22 2/27/23 2/29/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,886 2,633 4,948 6,359 6,076 6,839 8,230 9,115
EBITDA 1 753.7 832.1 1,033 1,314 941.4 1,238 1,523 1,777
EBIT 1 699.6 757 905.6 1,136 708.4 980.7 1,295 1,455
Operating Margin 37.1% 28.76% 18.3% 17.87% 11.66% 14.34% 15.74% 15.96%
Earnings before Tax (EBT) 1 584.6 758.9 890.2 1,136 701.7 1,000 1,349 1,492
Net income 1 585.6 645.8 782.3 970.9 592.6 844.9 1,125 1,258
Net margin 31.06% 24.53% 15.81% 15.27% 9.75% 12.36% 13.67% 13.8%
EPS 2 1.220 1.350 1.620 2.010 1.230 1.755 2.336 2.611
Free Cash Flow 1 - - 491.9 -59.98 -330.7 -687 1,152 1,106
FCF margin - - 9.94% -0.94% -5.44% -10.05% 14% 12.13%
FCF Conversion (EBITDA) - - 47.62% - - - 75.63% 62.26%
FCF Conversion (Net income) - - 62.87% - - - 102.37% 87.93%
Dividend per Share 2 0.3700 0.4100 0.4900 0.6100 0.3800 0.5165 0.6748 0.7269
Announcement Date 2/28/20 2/25/21 2/25/22 2/27/23 2/29/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 S1 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 1,937 1,936 - 1,681 1,385 2,039 3,424 1,305 1,770 3,076 1,146 1,854 1,889 1,379 2,145 - -
EBITDA 1 - - - - - - - - - - - - 574 124.9 126.3 - -
EBIT 1 - 258.2 - 338.1 242.5 313.8 556.3 243.1 274.5 - 93.55 - 292.6 141.8 173.1 - -
Operating Margin - 13.34% - 20.12% 17.51% 15.39% 16.25% 18.63% 15.5% - 8.16% - 15.49% 10.29% 8.07% - -
Earnings before Tax (EBT) - - - - - - - - - - - - - - - - -
Net income 1 360.6 227 - - - 293.5 497.7 - 224.1 424.6 89.79 78.16 336.5 143.6 172.5 - -
Net margin 18.62% 11.73% - - - 14.39% 14.54% - 12.66% 13.81% 7.84% 4.21% 17.81% 10.42% 8.04% - -
EPS 2 - 0.4700 - 0.5600 0.4300 0.6000 - 0.4200 0.4600 - 0.1900 0.1600 0.5805 0.3346 0.4146 - -
Dividend per Share 2 - - - - - - - - - - - - 0.5661 - - - 0.6640
Announcement Date 8/30/21 2/25/22 4/25/22 7/20/22 10/28/22 2/27/23 2/27/23 4/28/23 8/29/23 8/29/23 10/30/23 2/29/24 - - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - - 1,576 1,269 1,013 1,271 1,485 1,862
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - 492 -60 -331 -687 1,152 1,106
ROE (net income / shareholders' equity) 18.7% 13.5% 14.6% 15.8% 8.31% 11.3% 13.3% 13.6%
ROA (Net income/ Total Assets) 16.6% 12.1% 11.8% 12% 6.86% 9.08% 10.7% 11.3%
Assets 1 3,521 5,344 6,610 8,093 8,643 9,307 10,507 11,096
Book Value Per Share 2 9.480 10.50 11.90 13.80 14.40 15.70 17.60 19.30
Cash Flow per Share 2 0.7600 1.470 2.640 1.320 1.450 2.360 2.940 3.290
Capex 1 450 763 784 695 1,030 591 452 484
Capex / Sales 23.88% 28.97% 15.85% 10.93% 16.96% 8.64% 5.49% 5.31%
Announcement Date 2/28/20 2/25/21 2/25/22 2/27/23 2/29/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Bloomage BioTechnology Corporation Limited

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
61.1 CNY
Average target price
72.07 CNY
Spread / Average Target
+17.95%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED Stock Bloomage BioTechnology Corporation Limited
-8.71% 4.27B
CSL LIMITED Stock CSL Limited
-1.62% 89.22B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 40.49B
BIOGEN INC. Stock Biogen Inc.
-15.73% 32.79B
UCB Stock UCB
+64.13% 26.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-21.28% 14.52B
INCYTE CORPORATION Stock Incyte Corporation
-8.50% 13.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-44.07% 11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-13.06% 11.5B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.94% 8.82B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 688363 Stock
  4. Financials Bloomage BioTechnology Corporation Limited